Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy

Bibliographic Details
Main Authors:	Anne Montfort, Céline Colacios, Thierry Levade, Nathalie Andrieu-Abadie, Nicolas Meyer, Bruno Ségui
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-10-01
Series:	Frontiers in Immunology
Subjects:	tumor necrosis factor (TNF) PD-1 CTLA-4 melanoma immune escape
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2019.02515/full

Similar Items

The TNF Paradox in Cancer Progression and Immunotherapy
by: Anne Montfort, et al.
Published: (2019-07-01)

Anti-TNF, a magic bullet in cancer immunotherapy?
by: Anne Montfort, et al.
Published: (2019-11-01)

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
by: Fatima Bilal, et al.
Published: (2019-04-01)

The Tricyclodecan-9-yl-xanthogenate D609 Triggers Ceramide Increase and Enhances FasL-Induced Caspase-Dependent and -Independent Cell Death in T Lymphocytes
by: Bruno Ségui, et al.
Published: (2012-07-01)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
by: Florie Bertrand, et al.
Published: (2017-12-01)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
by: Maite Alvarez, et al.
Published: (2019-06-01)

New Insights into the Role of Sphingolipid Metabolism in Melanoma
by: Lorry Carrié, et al.
Published: (2020-08-01)

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
by: Claudia Ceci, et al.
Published: (2020-11-01)

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
by: Yousef R. Badran, et al.
Published: (2019-08-01)

Cell-mediated immunotherapy: its role in cancer treatment
by: Deshpande, Janhavee
Published: (2017)

Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
by: Laurence Pellerin, et al.
Published: (2020-10-01)

Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor zVAD-fmk.
by: Elodie Lafont, et al.
Published: (2010-01-01)

Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
by: Jun Zhang, et al.
Published: (2018-09-01)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
by: Catarina Nascimento, et al.
Published: (2020-05-01)

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
by: Yinghao Zhao, et al.
Published: (2018-05-01)

The use of immunotherapy in the treatment of melanoma
by: Tala Achkar, et al.
Published: (2017-04-01)

Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01)

Pseudoprogression in patients on immunotherapy
by: D. I. Yudin, et al.
Published: (2019-06-01)

Immunotherapy in genitourinary malignancies
by: Kathan Mehta, et al.
Published: (2017-04-01)

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01)

Immunotherapy in Colorectal Cancer: Current and Future Strategies
by: Akira Ooki, et al.
Published: (2021-01-01)

Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
by: Karishma R. Rajani, et al.
Published: (2019-02-01)

Intestinal microbiota: a new force in cancer immunotherapy
by: Zhujiang Dai, et al.
Published: (2020-06-01)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
by: Cai J, et al.
Published: (2019-10-01)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
by: Qi X, et al.
Published: (2017-12-01)

Immunotherapy for Prostate Cancer: Where We Are Headed
by: Giuseppe Schepisi, et al.
Published: (2017-12-01)

Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
by: Sultana Mehbuba Hossain, et al.
Published: (2021-07-01)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
by: Diogo Garcia, et al.
Published: (2021-06-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
by: Amisha Singh, et al.
Published: (2021-04-01)

Impact du système immunitaire dans le mélanome métastatique : étude de son rôle pronostique et prédictif.
by: Jacquelot, Nicolas
Published: (2016)

Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies
by: Silvia Martina Ferrari, et al.
Published: (2019-05-01)

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
by: Daniel Zingg, et al.
Published: (2017-07-01)

Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
by: Lin Shui, et al.
Published: (2020-01-01)

Curcumin as an Adjuvant to Cancer Immunotherapy
by: Silpita Paul, et al.
Published: (2021-08-01)

Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011
by: Forero Ivan, et al.
Published: (2012-05-01)

IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis.
by: Emmanuel Mas, et al.
Published: (2009-11-01)

Is There a Role for Immunotherapy in Prostate Cancer?
by: Alessandro Rizzo, et al.
Published: (2020-09-01)

A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas
by: Varun Monga, et al.
Published: (2020-07-01)